Ylä-Herttuala S - Search Results

1

VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.

Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Söderberg O, Anisimov A, Kholová I, Pytowski B, Baldwin M, Ylä-Herttuala S, Alitalo K, Kreuger J, Claesson-Welsh L. Nilsson I, et al. EMBO J. 2010 Apr 21;29(8):1377-88. doi: 10.1038/emboj.2010.30. Epub 2010 Mar 11. EMBO J. 2010. PMID: 20224550 Free PMC article.

2

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K. Mäkinen T, et al. Nat Med. 2001 Feb;7(2):199-205. doi: 10.1038/84651. Nat Med. 2001. PMID: 11175851

3

Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, Alitalo K. Karpanen T, et al. Cancer Res. 2001 Mar 1;61(5):1786-90. Cancer Res. 2001. PMID: 11280723

4

Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.

Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. Enholm B, et al. Circ Res. 2001 Mar 30;88(6):623-9. doi: 10.1161/01.res.88.6.623. Circ Res. 2001. PMID: 11282897

5

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. He Y, et al. J Natl Cancer Inst. 2002 Jun 5;94(11):819-25. doi: 10.1093/jnci/94.11.819. J Natl Cancer Inst. 2002. PMID: 12048269

6

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K. Saaristo A, et al. FASEB J. 2002 Jul;16(9):1041-9. doi: 10.1096/fj.01-1042com. FASEB J. 2002. PMID: 12087065

7

Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor.

Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Ylä-Herttuala S, Alitalo K. Petrova TV, et al. EMBO J. 2002 Sep 2;21(17):4593-9. doi: 10.1093/emboj/cdf470. EMBO J. 2002. PMID: 12198161 Free PMC article.

8

Lymphangiogenic gene therapy with minimal blood vascular side effects.

Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, Bueler H, Ylä-Herttuala S, Alitalo K. Saaristo A, et al. J Exp Med. 2002 Sep 16;196(6):719-30. doi: 10.1084/jem.20020587. J Exp Med. 2002. PMID: 12235206 Free PMC article.

9

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. Rissanen TT, et al. Circ Res. 2003 May 30;92(10):1098-106. doi: 10.1161/01.RES.0000073584.46059.E3. Epub 2003 Apr 24. Circ Res. 2003. PMID: 12714562

10

Gene transfer as a tool to induce therapeutic vascular growth.

Ylä-Herttuala S, Alitalo K. Ylä-Herttuala S, et al. Nat Med. 2003 Jun;9(6):694-701. doi: 10.1038/nm0603-694. Nat Med. 2003. PMID: 12778168 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

772 results

Search Page

Filters